Nykredit A/S’s Tarsus Pharmaceuticals TARS Stock Holding History

Nykredit A/S’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$106K	Buy	+1,679	New	+$107K	﹤0.01%	1299

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Nykredit A/S's TARS Position: Q2 2026 in Review

Nykredit A/S opened a new position in Tarsus Pharmaceuticals (TARS) in Q2 2026: 1,679 shares worth $106K. The stake represents ﹤0.01% of the portfolio and ranks #1299 among its holdings.

165 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

Nykredit A/S held 1,679 shares of Tarsus Pharmaceuticals worth $106K as of Q2 2026.
Tarsus Pharmaceuticals was a new Nykredit A/S position in Q2 2026.
Tarsus Pharmaceuticals made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1299 holding.
165 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.